XYMOGEN SUBSIDIARY PHARMACEUTIX MEDICAL FOODS ANNOUNCES DUCK WILLIAMS AS VICE PRESIDENT
Orlando, Fla. – Thursday, November 15, 2012 – Pharmaceutix Medical Foods, a wholly owned subsidiary of XYMOGEN, announced today that Duck Williams has been named Vice President of the company.
Williams has more than 25 years of experience in the pharmaceutical industry and was previously a sales manager for Pamlab LLC for almost 15 years. During his time at Pamlab, the company was one of the first to market medical food products on a larger, national scale.
“Many medical foods have been shown to be therapeutic and actually help treat the disease causation of certain diseases and illnesses,” said Williams. “As a general rule, however, they don’t have the serious side effects that drugs do and this is the primary reason for the rapid growth of medical foods over the past five to six years. Truly, medical foods are the best of both worlds because you have a product that is ‘drug-like’ in its treatment of a disease but, it doesn’t have the negative side effects.”
Williams is eager to join the team at Pharmaceutix Medical Foods and applauds XYMOGEN for introducing new products to its current and potential customers.
“The world of medical foods is not that far from the world of functional medicine products,” Williams said. “XYMOGEN is a company that is looking to grow and expand and there is great potential to introduce new products to help an even larger base of the patient population.”
Williams is a graduate of Auburn University with a bachelor’s of science degree in Sociology.
For more information, visit www.pharmaceutixhealth.com
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. As a nutraceutical company, it has introduced numerous innovations to the functional medicine community. XYMOGEN’s Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties. The company’s unprecedented growth continues with a new, state-of-the-art 136,000 square foot manufacturing facility and laboratory, as well as a strategic expansion into Canada and Australia, two of the largest international markets. XYMOGEN’s strength as a company was reinforced in 2007, 2008, 2010, and 2011, when it was recognized by Inc. magazine as one of the 5000 fastest-growing private companies in America.
For more information, visit www.xymogen.com.
Please email email@example.com for comments or inquiries.
# # #
For information, contact:
Sara R. Brady